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Epstein-Barr Virus (EBV) infects nearly all humans
and then persists for the life of the host. In some
people who later develop cancer , EBV DNA is
present within malignant cells and circulates at el-
evated levels in the plasma. In the current study, we
validated five novel quantitative polymerase chain
reaction (Q-PCR) assays targeting disparate but
highly conserved segments of the EBV genome
(BamH1W , EBNA1 , LMP1 , LMP2 , and BZLF1). Each
assay was sensitive to as few as 50 copies of EBV
DNA per reaction and was linear across at least four
orders of magnitude. When applied to paraffin-em-
bedded tissues in concert with EBV-encoded RNA
(EBER) in situ hybridization, the BamH1W and
EBNA1 assays were the most informative , while use
of the entire battery of EBV PCR assays may help
identify genomic polymorphisms or deletions.
Higher viral loads were found in the 17 EBER-posi-
tive compared with the 13 EBER-negative tumors
(means 84,978 versus 22 copies of EBV per 100,000
cells , respectively). The five Q-PCR assays were also
informative in plasma samples where EBV was mea-
surable in all nine patients with lymphoma or in-
fectious mononucleosis , whereas EBV was unde-
tectable in all nine healthy controls. The findings
suggest that Q-PCR is an effective method of distin-
guishing disease-associated virus from incidental
virus in paraffin-embedded tissue and in plasma
samples. (J Mol Diagn 2004, 6:378–385)
Epstein-Barr virus (EBV) has been implicated in the patho-
genesis of several malignancies including non-Hodgkin
and Hodgkin lymphomas and nasopharyngeal carcino-
ma.1,2 Recent studies suggest that EBV DNA is present in
tissues of more types of cancer than originally thought,
including EBV-encoded RNA (EBER)-negative Burkitt and
Hodgkin lymphomas, and breast and lung adenocarcino-
mas.3–7 These data are controversial, in large part because
some laboratory assays for EBV are not designed to spe-
cifically detect tumor-associated EBV or to distinguish it
from the EBV normally carried in a small proportion of be-
nign B lymphocytes by most humans.
The assay that many consider to be the gold standard
for identifying tumor-associated virus is EBER in situ hy-
bridization. Results are interpreted morphologically so
that latent virus can be localized to malignant versus
benign cell types. The accuracy of EBER in situ hybrid-
ization has recently been called into question by investi-
gators who showed that EBV was present, based on
positive molecular or immunohistochemical assays, in
certain EBER-negative tumors.3–5,7–11 To explain some of
these discrepancies, the “hit and run” hypothesis has
been put forward: it states that segments of EBV DNA or
EBV gene products are undetected in certain cells or in
entire tumors because portions of the EBV genome have
been lost or rearranged or integrated into host chromo-
somal DNA.4,5 An alternative possibility is that certain
molecular or immunohistochemical assays for EBV are
non-specific, resulting in false-positive interpretations of
tumor-associated EBV.
In the current study, we developed and validated a
battery of new quantitative real-time PCR (Q-PCR) as-
says targeting five different parts of the EBV genome.
To assess their utility in detecting disease-related EBV,
these assays were applied in a pilot series of paraffin-
embedded tissues on which EBER in situ hybridization
had also been performed. Furthermore, the assays
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were applied to several plasma samples to assess their
suitability for use in studies in which patients are
screened for an EBV-related disease.
Materials and Methods
Patient Samples and Cell Line Controls
Paraffin blocks (n  35) and plasma samples (n  18)
were retrieved from the archives of our clinical and re-
search laboratories under the supervision of our Institu-
tional Review Board. Cases were selected to represent
various EBV-related diseases and controls. EBER in situ
hybridization was performed on paraffin sections using a
fluorescein-labeled oligonucleotide probe targeting
EBER RNA (Biogenex, San Ramon, CA) and the Inno-
genex ISH DAB Kit (Biogenex). A fluorescein-labeled
oligonucleotide Oligo d(T) probe (Biogenex) served as a
control for RNA preservation in the histological sections.
A tumor was considered EBV-related if the EBER signal
was localized to at least one definite malignant cell. A
case was considered EBER-negative if EBER staining
was undetected or was apparent only in benign-appear-
ing lymphoid cells.
Sterile procedure was used during histological sec-
tioning to prevent tissue carryover between cases. Before
sectioning each block, the work area and forceps were
wiped down with 10% bleach in water and rinsed with
deionized water. Disposable blades were either dis-
carded or moved to an unused edge before cutting each
block. Two 10-m thick sections from each block were
placed into microfuge tubes for subsequent DNA extrac-
tion. Five-m thick sections were placed on glass slides
for histochemical staining procedures.
To extract DNA from paraffin-embedded tissue sec-
tions, deparaffination was performed using three washes
in xylene for 10 minutes at room temperature followed by
two washes in 100% ethanol to remove the xylene. Tis-
sues were dried at 55°C and digested overnight at 55°C
in 100 l of TEN buffer (10 mmol/L Tris-HCl pH 8.0, 1
mmol/L EDTA pH 8.0, 20 mmol/L NaCl) containing 20
mg/ml proteinase K, and then the proteinase was inacti-
vated at 95°C for 10 minutes. Undigested tissue rem-
nants were pelleted by centrifugation at 14,000 rpm for
10 minutes. The supernatant containing extracted DNA
was transferred to a new microfuge tube and stored at
20°C until use.
Plasma samples were selected from nine patients, four
of whom had EBV-related malignancy as shown by EBER
in situ hybridization on biopsy materials, and five with
infectious mononucleosis confirmed by heterophile anti-
body positivity. Plasma was also obtained from nine
healthy blood donors. Total DNA was extracted from 200
l of plasma using the QIAmp Blood Kit (Qiagen Inc.,
Valencia, CA). Before extraction, the plasma was spiked
with 2 l of IPC (TaqMan Exogenous Internal Positive
Control DNA, Applied Biosystems (ABI), Foster City, CA)
to control for the effectiveness of extraction and amplifi-
cation. Purified DNA was eluted into 50 l of AE buffer
(Qiagen).
DNA from the Namalwa cell line (two copies of EBV per
cell, equivalent to 3  105 copies of EBV/g DNA) was
used as a standard by which EBV genomic DNA was
measured (American Type Culture Collection, Rockville,
MD). DNA from the Raji Burkitt lymphoma line and the
P3HR-1 Burkitt cell line were used as additional EBV-
related lymphoma cell line controls (American Type Cul-
ture Collection). DNA was extracted from fresh cell pel-
lets using the Purgene DNA Isolation kit (Gentra,
Minneapolis, MN). Serial 10-fold dilutions of these DNAs
were made in nuclease-free water to examine the linearity
of each quantitative PCR assay. Potential cross-reactivity
with other viruses or genomic DNA was evaluated by
BLAST sequence analysis. Specificity testing was per-
formed on purified cytomegalovirus (CMV) and Kaposi’s
sarcoma-associated herpesvirus (KSHV) DNA (Ad-
vanced Biotechnologies, Inc., Columbia, MD) and on
paraffin-embedded tissue from five patients diagnosed
with other herpes family viruses (three with CMV and two
with herpes simplex).
Development and Validation of Quantitative
PCR Assays
EBV genomic sequences were downloaded from Gen-
Bank (www.ncbi.nlm.nih.gov). PCR primers and TaqMan
probes targeting conserved portions of the reiterated
BamH1W segment and the unique EBNA1, LMP1, LMP2,
and BZLF1 genes were designed using Primer Express 2.0
software (ABI). These sequences are shown in Table 1.
Primers and TaqMan probe targeting the cellular ApoB
gene, as described by Sanchez and Storch,11 served as
a control for the efficacy of extraction and amplification of
DNA from paraffin-embedded tissue. Using the Namalwa
cell line as a standard, ApoB DNA was measured in each
tissue sample. The quantity and quality of extracted DNA
was considered adequate if ApoB measurement indi-
cated that at least 50 cells were present in the PCR
reaction. In the experimental samples, the minimum num-
ber of cells evaluated per PCR reaction was 94.
PCR was performed and products were detected us-
ing an ABI Prism 7900 Real-Time PCR instrument and
Sequence Detection System software. Thermocycling
conditions were: 50°C for 2 minutes; 95°C for 10 minutes;
95°C for 15 seconds and 60°C for 1 minute for 40 cycles.
Each 50-l reaction contained: 1X TaqMan Universal
Master Mix, forward and reverse primer (15 mol each),
and TaqMan probe (10 mol). DNA template volume was
1 l for paraffin tissues, and 5 l for plasma samples. The
plasma reactions also contained 1X IPC Master Mix (ABI)
to co-amplify the spiked IPC sequence. To improve assay
sensitivity when targeting LMP1 and BZLF1 genes, 30
mol each of the forward and reverse primers was used.
To check for amplicon contamination, every run con-
tained at least two “no template” controls in which nucle-
ase-free H2O was substituted for template. A standard
curve was generated using 10-fold dilutions of Namalwa
DNA varying from 50,000 to 0.5 copies of EBV DNA, and
this curve was considered acceptable if a difference of
3.3 /0.3 cycles was demonstrated between each of
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the 10-fold dilutions, and if the correlation coefficient was
at least 0.99. Quantification results for experimental sam-
ples were extrapolated from the standard curve. Experi-
mental samples were run in duplicate and a mean viral
load was calculated.
EBV viral load in paraffin tissue was calculated based on
the ratio of copies of EBV to ApoB in a given volume of
extracted DNA, with ApoB representing the number of cells
in the sample. The resulting ratio was then multiplied by
100,000 to provide the number of copies of EBV per
100,000 cells. For plasma samples, EBV viral load was
expressed in copies per ml of plasma. Plasma results were
considered negative for EBV when the spiked IPC control
sequence was amplifiable while EBV DNA was not. For
purposes of data analysis, samples with no measurable
EBV DNA were reported as having a viral load of zero.
Qualitative LMP2 Gene PCR Assay
To further investigate a case in which the LMP2 segment
selectively failed to amplify by Q-PCR, a second primer
set was designed to amplify a 130-bp region of the LMP2
gene encompassing the 69-bp segment that had been
targeted by the standard LMP2 Q-PCR primers. This
qualitative PCR used the following primer sequences:
LMP2Ext forward 5-CTGTTTTGCAGCTGAGTCC-3 and
LMP2Ext reverse 5-CAATGTTAAAAGGGCTGCACC-3.
The 50-l PCR reaction consisted of: 1X PCR Buffer, 2
mmol/L MgCl2 2.5 units Platinum TaqDNA Polymerase
(Invitrogen, Carlsbad CA), 0.2 mmol/L dNTPs (ABI), 50
mol of each primer, and nuclease-free water. Reaction
conditions were: 95°C for 2 minutes; 35 cycles of 95°C for
30 seconds, 60°C for 30 seconds, and 72°C for 1 minute;
and then 72°C for 10 minutes. Products were electropho-
resed in a 2% agarose gel containing 0.5 mg/ml ethidium
bromide. DNA from Case 7 (EBER-positive AIDS lym-
phoma) and an EBER-positive gastric carcinoma were
used as wild-type controls.
LMP1, LMP2, and BZLF1 Expression by
Immunohistochemistry
In selected cases with atypical DNA amplification results,
immunostains were used to assess viral gene expression.
Immunohistochemical analysis for LMP1 and LMP2 was
performed on paraffin sections using the Anti-EBV LMP1-
clone CS1–4 cocktail of mouse monoclonal antibodies
(Dako, Carpinteria, CA) and the TP/LMP2a-clone E411 rat
monoclonal antibody (Asencion, Munich, Germany). An-
tigen retrieval (Biogenex Citrate Antigen Retrieval Buffer,
HK086–9K) was performed for 30 minutes, and endoge-
nous peroxidase was quenched for 10 minutes using
Peroxidase Quenching Solution (Zymed, San Francisco,
CA). Bound antibody was detected using the Zymed
PicTure-Plus Kit with Polymer Detection System
(Zymed).12 Common antibody diluent (Biogenex HK156–
5K) was used to dilute the LMP1 (1:100) and LMP2 (1
mg/ml) antibodies, and sections were incubated with
primary antibody for 40 minutes. Bound antibody was
detected with a ready-to-use -rat-HRP polymer conju-
gate for 30 minutes (LMP1) or 20 minutes (LMP2), fol-
lowed by diamino-benzidine (DAB) chromogen (Dako
Liquid Dab and Substrate Chromogen System K3468).
Tissues were counter-stained with hematoxylin (Dako).
EBER-positive Hodgkin lymphoma slides served as pos-
Table 1. Sequences of Primers and TaqMan Probes Used for Real-Time PCR
BamH1W Forward 5-GCA GCC GCC CAG TCT CT-3
Reverse 5-ACA GAC AGT GCA CAG GAG CCT-3
Probe 5-(6FAM)AAA AGC TGG CGC CCT TGC CTG(TAMRA)-3
Amplicon size 83 bp
Nucleotide # 47257 to 47340
EBNA1 Forward 5-TAC AGG ACC TGG AAA TGG CC-3
Reverse 5-TCT TTG AGG TCC ACT GCC G-3
Probe 5-(6FAM)AGG GAG ACA CAT CTG GAC CAG AAG GC(TAMRA)-3
Amplicon size 78 bp
Nucleotide # 107970 to 108048
LMP1 Forward 5-CAG TCA GGC AAG CCT ATG A-3
Reverse 5-CTG GTT CCG GTG GAG ATG A-3
Probe 5-(6FAM)GTC ATA GTA GCT TAG CTG AAC(TAMRA)-3
Amplicon size 104 bp
Nucleotide # 168117 to 168221
LMP2 Forward 5-AGC TGT AAC TGT GGT TTC CAT GAC-3
Reverse 5-GCC CCC TGG CGA AGA G-3
Probe 5-(6FAM)CTG CTG CTA CTG GCT TTC GTC CTC TGG(TAMRA)-3
Amplicon size 69 bp
Nucleotide # 679 to 748
BZLF1 Forward 5-AAA TTT AAG AGA TCC TCG TGT AAA ACA TC-3
Reverse 5-CGC CTC CTG TTG AAG CAG AT-3
Probe 5-(6FAM)ATA ATG GAG TCA ACA TCC AGG CTT GGG C(TAMRA)-3
Amplicon size 91 bp
Nucleotide # 102214 to 102305
Nucleotide # refers to location in the prototypic EBV B95.8 genome sequence (GenBank Accession No. V01555). The BamH1W reverse primer
sequence matches EBV from the P3HR-1 cell line, and it is one nucleotide different from the prototypic B95.8 strain; this difference did not significantly
affect viral loads.
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itive controls. Results were interpreted microscopically
by looking for cytoplasmic and membrane localization of
the chromagen in neoplastic cells.
Immunohistochemical analysis of the EBV BZLF1 pro-
tein using the Zebra clone BZ.1 antibody (Dako, 1:25
dilution) was performed as described above except for
the following modifications. All washes after antigen re-
trieval were performed in Automation Buffer (Biomeda
Corp, Foster City, CA). Endogenous peroxidase was
quenched using Peroxidase Block (Dako) for 10 minutes
at 37°C. To reduce non-specfic binding, Avidin and Biotin
blocks (Dako) were performed for 15 minutes followed by
Protein Block (Biogenex) for 10 minutes at 37°C. Sections
were incubated with primary antibody for 30 minutes at
37°C, and bound antibody was detected using the Bio-
genex StrAviGen Multi Link Kit (Biogenex). Sections were
incubated with secondary antibody (1:20) for 8 minutes at
37°C followed by incubation with HRP label (1:20; diluted
with Biogenex Streptavidin-Peroxidase Diluent) for 8 min-
utes at 37°C. An oral hairy leukoplakia section served as
a positive control. Results were interpreted microscopi-
cally by looking for nuclear localization of the chromagen
in neoplastic cells.
Results
Sensitivity of the Q-PCR Assays
Five different real-time PCR assays targeting various seg-
ments of the EBV genome (BamH1W, EBNA1, LMP1,
LMP2, BZLF1) were developed and tested using 10-fold
serial dilutions of Namalwa cell line DNA as a standard.
All five assays consistently detected as few as 50 copies
of DNA from the Namalwa, Raji, and P3HR-1 cell lines,
and individual assays sometimes detected as few as 5 or
0.5 copies per PCR.
Assay Linearity
The BamH1W assay was linear across five orders of
magnitude from 0.5 to 50,000 copies of Namalwa EBV
DNA. The EBNA1, LMP2, and BZLF1 assays were linear
across four orders of magnitude (from 5 to 50,000 copies)
and the LMP1 assay was linear across three orders of
magnitude (from 50 to 50,000 copies). The assays were
efficient as shown by a cycle difference for each 10-fold
dilution ranging between 3.3 and 3.4 (representing slope
of the standard curve). The assays were linear as shown
by a correlation coefficient greater than 0.99 (represent-
ing the linearity of the standard curve). Serial dilutions of
DNA from the Raji cell line and the P3HR1cell line were
also used to examine assay linearity. All five novel real-
time PCR assays detected both Raji and P3HR1 EBV in a
linear fashion (correlation coefficient 0.99), and cycle
difference between each 10-fold dilution averaged 3.5 for
Raji and 3.3 for P3HR1.
Application of the Viral Load Assays to Paraffin-
Embedded Tissues
EBV viral load was measured on 30 paraffin-embedded
tissues representing various EBV-related diseases (17
EBER-positive lymphomas or carcinomas) and controls (13
EBER-negative lymphomas) using each of the five validated
real-time PCR assays. ApoB, a cellular gene, was co-am-
plified and used as a normalizer by which to control for the
number of cells tested, and to check for inhibitors of ampli-
fication or failed extraction. None of the 30 tumors in this
study had to be excluded because of inadequate ApoB
control amplification. Results, expressed as copies of EBV
per 100,000 cells, are shown in Table 2.
All 17 of the EBER-positive tumors had detectable EBV
by at least two of the five Q-PCR assays, and 13 cases
had measurable EBV by all five Q-PCR assays. EBER-
positive carcinomas and non-Hodgkin lymphomas had
the highest viral levels, while Hodgkin lymphoma cases
had quite variable viral loads in keeping with the varying
proportion of tumor cells in these tissues. Nine of the 13
EBER-negative tumors had low level EBV by at least one
assay, consistent with EBV-carrier status.
When viral load was high by one assay, it tended to be
high by the rest of the assays. Likewise, when viral load was
low by one assay it was either low or undetectable by the
other assays, suggesting varying lower limits of detection
among the assays. The BamH1W assay was most sensitive,
presumably because it targets a reiterated sequence that is
present at approximately 10 copies per EBV genome. The
EBNA1 assay was the next most sensitive to EBV-related
malignancy, while the LMP1, LMP2, and BZLF1 assays
were more prone to false-negative results.
Partial deletion or polymorphism of the EBV genomes
could explain, at least in part, the differential productivity of
the viral load assays in a given tumor. Case 8 had dropout
of two EBV markers, suggesting that it had defective LMP1
and BZLF1 segments. An even more striking differential was
seen in Case 6, where the LMP2 gene was not amplified
despite high levels of EBV DNA by the other four assays.
When tested using an alternate primer set, Case 6 still had
no amplifiable LMP2 DNA, suggesting that this tumor had a
global defect in the EBV LMP2 region such as gene deletion
or chromosomal integration. Further support for this inter-
pretation comes from immunohistochemical staining which
revealed no LMP2 protein expression. Likewise, Case 8 did
not express LMP1 or BZLF1 by immunohistochemistry, in
keeping with our inability to amplify LMP1 and BZLF1 at the
DNA level. While lack of protein expression is consistent
with a genetic defect, it is certainly not diagnostic of a
genetic defect. Further work is required to explore why
selected segments of EBV DNA failed to amplify in these
two AIDS lymphomas.
Human Plasma Samples
To test the versatility of these Q-PCR assays for an alter-
nate sample type, we measured EBV viral load in plasma
samples from nine patients with various EBV-related dis-
eases and nine healthy donors (Table 3). Consistently
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high EBV loads were seen in the four patients with EBV-
related malignancy and in the five infectious mononucle-
osis patients. In contrast, healthy individuals had no mea-
surable EBV DNA by any of the five assays. It appears
that the five Q-PCR assays are equally effective and
virtually interchangeable in terms of their correlation with
clinical status in this small cohort of plasma samples.
Assay Specificity
To test the extent to which the newly developed real-time
PCR assays cross-react with other common herpesvi-
ruses, we tested them on pure CMV and KSHV DNA and
on DNA extracted from paraffin-embedded lesional tis-
sue of patients with active CMV or herpes simplex virus
(HSV) infection (Table 4). No amplification was seen
when pure CMV or KSHV DNA served as the template or
when either of the herpes simplex lesions was assayed.
All three of the CMV-related colon lesions had low-level
EBV DNA by at least one assay. Since no amplification
was observed with purified CMV DNA, the EBV signal in
these colon biopsies could have emanated from rare
EBV-infected lymphocytes in the tissue. There is no evi-
dence for cross-reactivity with any of the viruses tested.
Assay Reproducibility
Reproducibility of the five Q-PCR assays and the ApoB
control assay was examined by replicate testing of 11
paraffin tissue samples including Cases 2, 7 to 12, and
15 representing EBER-positive tumors that span a range
of low to high viral loads, and Cases 21, 25, and 29 that
were EBER-negative. Each sample was amplified by all
six assays in duplicate on three different days for a total
of 396 measurements, or six for each analyte on each
sample. The coefficient of variance based on viral load
was: 19% for EBNA1, 23% for ApoB, 28% for BamH1W,
33% for LMP1, 39% for LMP2, and 43% for BZLF1. The
coefficient of variance based on cycle threshold (Ct) was:
1% for ApoB, 2% for BamH1W, 2% for EBNA1, 3% for
LMP1, 4% for LMP2, and 4% for BZLF1. These findings
suggest that the assays are quite precise and reproduc-





















1 Nasopharyngeal carcinoma 6,935 250,937 370,310 562,653 80,404 477,520
2 Nasopharyngeal carcinoma 15,313 32,822 24,202 253,366 34,108 51,584
3 Nasopharyngeal carcinoma 69,917 23,047 62,701 126,005 3,948 45,545
4 Lymphoma, diffuse large cell 6,178 58,514 197,685 142,878 13,419 133,716
5 Lymphoma, diffuse large cell 1,501 41,173 45,969 181,346 42,638 82,545
6 AIDS lymphoma 2,228 631,239 1,431,059 1,314,183 0 783,214
7 AIDS lymphoma 592 349,493 1,168,581 1,299,831 735,473 696,453
8 AIDS lymphoma 209 2,153 11,005 0 2,871 0
9 Hodgkin, AIDS-related 979 3,575 9,295 2,451 102 1,328
10 Hodgkin, AIDS-related 3,633 2,697 7,514 13,075 3,165 2,780
11 Hodgkin, AIDS-related 4,032 397 893 744 124 109
12 Hodgkin, AIDS-related 421 95 0 0 0 143
13 Hodgkin lymphoma 18,058 2,226 5,394 2,426 244 3,156
14 Hodgkin lymphoma 94 319 106 0 0 0
15 Post-transplant LPD 2,778 25,054 116,847 38,661 21,274 15,623
16 Post-transplant LPD 6,559 15,612 22,702 39,549 6,342 23,052
17 Post-transplant LPD 2,733 5,269 12,880 21,661 6,659 114,453
Mean viral load 84,978 217,946 285,631 67,912 162,081
Qualitative totals 17/17 16/17 14/17 14/17 15/17
EBER-negative cancers
18 AIDS lymphoma 60,348 5 3 8 0 5
19 AIDS lymphoma 50,966 57 84 47 0 33
20 AIDS lymphoma 41,928 0 0 0 0 0
21 AIDS lymphoma 32,544 34 38 55 4 9
22 AIDS lymphoma 18,094 6 11 33 0 0
23 AIDS lymphoma 14,180 21 42 0 0 21
24 AIDS lymphoma 12,626 8 16 0 0 8
25 AIDS lymphoma 691 0 0 0 0 0
26 Hodgkin lymphoma 11,660 21 13 21 0 6
27 Hodgkin lymphoma 4,203 2 0 0 0 0
28 Hodgkin lymphoma 1,182 42 59 0 0 0
29 Hodgkin lymphoma 1,551 0 0 0 0 0
30 Hodgkin lymphoma 643 0 0 0 0 0
Mean viral load 22 33 33 4 14
Qualitative totals 9/13 8/13 5/13 1/13 6/13
Each sample was tested in duplicate in each Q-PCR assay, and the values shown represent the mean EBV load for the specific assay normalized
to ApoB control values, ie, mean EBV copy number/ApoB copy number  100,000  EBV DNA copies per 100,000 cells. Samples with no measurable
EBV DNA are reported as having a viral load of zero. LPD, lymphoproliferative disorder.
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ible. When these assays are used for serial monitoring of
viral load in a given patient, changes in viral load beyond
the analytic variance of the assay are presumed to be a
consequence of change in clinical status.
Discussion
In this study, we validated five new real-time PCR assays,
each targeting a different part of the EBV genome. The
target genes were chosen because they encode prod-
ucts that are important in viral pathogenesis, and they
represent sequences that are highly conserved across all
EBV strains. We showed that the novel Q-PCR assays
targeting these gene segments were sensitive, specific,
linear, and reproducible in measuring EBV in cell lines as
well as in paraffin-embedded tissues and plasma from
patients with a wide variety of EBV-related diseases.
The BamH1W assay appears to be the most sensitive
of the five for detecting low-level virus, in keeping with the
fact that the target sequence is reiterated within each
viral genome. A drawback of using this assay is that the
number of reiterated BamH1W sequences varies among





copies/ml LMP1 copies/ml LMP2 copies/ml BZLF1 copies/ml
EBV-related disease
A Burkitt lymphoma 26,467 325,800 356,040 131,940 174,240
B AIDS lymphoma 81,119 628,920 510,660 247,800 284,280
C Post-transplant LPD 119,320 732,120 1,565,220 519,840 467,280
D Post-transplant LPD 2,423 8,400 20,340 11,220 10,980
E Infectious mono 13,003 35,940 99,420 16,140 10,500
F Infectious mono 912 2,640 3,900 660 516
G Infectious mono 676 2,040 4,020 318 780
H Infectious mono 399 4,620 18,840 3,000 2,760
I Infectious mono 351 780 4,320 402 198
Mean viral load 27,186 193,473 286,973 103,480 105,726
Healthy controls
J Blood donor 0 0 0 0 0
K Blood donor 0 0 0 0 0
L Blood donor 0 0 0 0 0
M Blood donor 0 0 0 0 0
N Blood donor 0 0 0 0 0
O Blood donor 0 0 0 0 0
P Blood donor 0 0 0 0 0
Q Blood donor 0 0 0 0 0
R Blood donor 0 0 0 0 0
Mean viral load 0 0 0 0 0
Each sample was tested in duplicate in each Q-PCR assay, and the values shown represent the mean EBV load for the specific assay. Samples
with no measurable EBV DNA are reported as having a viral load of zero. LPD, lymphoproliferative disorder; Mono, mononucleosis.

















0* 0 0 0 0 0
32 Colon biopsy,
CMV colitis
145 1 0 0 0 4
35 Colon biopsy,
CMV colitis
2,033 7 6 1 1 9
36 Colon biopsy,
CMV colitis












2.6† 0 0 0 0 0
*, Purified CMV DNA contains no human DNA, and therefore lack of ApoB DNA is expected.
†, Purified KSHV DNA contains low level ApoB, suggesting that residual human DNA emanated from the cell line from which this purified virus was
prepared.
CMV, cytomegalovirus; KSHV, Kaposi’s sarcoma associated herpesvirus; HSV, herpes simplex virus.
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EBV strains, typically ranging between 7 and 11 repeats
per genome. If the BamH1W copy number of a patient’s
EBV strain differs from that of the Namalwa Burkitt lym-
phoma standard, then we will overestimate or underesti-
mate the viral genome copy number in proportion to that
difference. This variability confounds our ability to pre-
cisely quantitate the number of viral genomes, but this
deficiency might be outweighed by the assay’s exquisite
sensitivity to low-level virus, which could help detect early
stage disease or help monitor residual disease burden
after therapy. The EBNA1 Q-PCR appears to be the next
most sensitive assay among the five that were devel-
oped; it targets a single copy highly conserved gene that
is thought to be essential for maintaining the virus long-
term in dividing cells.
The true viral load in a given tumor could not be es-
tablished because viral load varied, sometimes quite
substantially, depending on which assay was used. The
explanation for this variability was not always evident. If a
partial inhibitor in a given tumor sample is assumed to
inhibit all five assays equally, then inhibitors cannot ex-
plain the variance in viral loads by assay in a given tumor.
The variance is especially striking given that the same
Namalwa cell line was used as a standard for each of the
five viral load assays. However, Namalwa DNA might
contain a sequence variant that selectively affects bind-
ing of one primer or probe, thus rendering a given assay
differentially efficient compared to the other assays.
Despite our efforts to target highly conserved gene
sequences, two tumors (Cases 6 and 8, both AIDS lym-
phomas) had selective dropout of amplifiable EBV DNA
at the BZLF1, LMP1, or LMP2 loci. If a multiplicity of EBV
assays had not been used in this study, then these cases
might have been falsely characterized as negative for
EBV. Furthermore, the selective failure of a given PCR
assay suggests that a genetic defect is present, and this
defect could potentially contribute to disease pathogen-
esis. For example, BZLF1 encodes an immediate early
lytic protein that is critical in controlling the latent versus
replicative phases of viral infection. LMP1 protein has
growth-promoting properties, which imply a role in tumor
promotion or maintenance. LMP2, also located on the cell
surface, acts to promote survival of B cells that are crip-
pled by lack of functional antigen receptors. LMP2 is
transcribed across the terminal repeat sequences, an
area of the genome known to be involved in integration
events. The Q-PCR assays described herein could pro-
vide a mechanism to screen for gene abnormalities in-
cluding deletion, polymorphism, or integration. Such
events can be further investigated by designing new up-
or down-stream primers sets to map a putative deletion,
and by sequencing the defective region to look for poly-
morphisms that interfere with primer or probe binding.
Another advantage of the Q-PCR assays described
herein is that they are rapid and less labor intensive (3.5
hours total; 1 hour technologist time) than manual EBER
in situ hybridization (7 hours total; 3 hours technologist
time). Q-PCR is automated to facilitate high throughput,
and is less subject to amplicon contamination than are
traditional PCR assays in which product is detected by
gel or by enzyme-linked immunoassay (ELISA). To im-
prove these Q-PCR assays further, we recently showed
that all components could be halved to make a 25-l total
reaction volume, and products could be amplified
equally well on the ABI 7000 or 7700 instruments (Ap-
plied BioSystems) with little if any effect on outcome (data
not shown).
Paraffin-embedded tissues representing EBV-related
non-Hodgkin lymphomas and carcinomas had consider-
ably higher EBV loads than did the EBER-negative tu-
mors. These results suggest the possibility of using a
rapid real-time PCR to screen for EBV, followed by EBER
in situ hybridization on equivocal cases to distinguish
tumor-associated virus from incidental viral infection. It
appears that a threshold value of around 100 EBV copies
per 100,000 cells distinguishes EBER-positive from
EBER-negative cancers. This screening strategy is less
likely to be useful for Hodgkin lymphoma cases, given the
paucity of tumor cells and the associated low viral loads
that approach the levels found in EBER-negative tumors.
Finally, the applicability of the five Q-PCR assays to
plasma samples was demonstrated in a pilot series of
cases. While all five assays yielded similar results in the
nine cases we examined, we predict that future studies
will show preferential amplification in certain strains of
EBV, as was found in the biopsy samples we studied. The
advantage of testing plasma as opposed to biopsy ma-
terial is the less invasive sample collection and the ability
to screen for lesions that are not yet clinically apparent.
Prior studies suggest that EBV viral load testing of plasma
samples is useful in at least two clinical situations. First,
healthy allogeneic transplant patients usually have
plasma levels below 700 copies per ml, whereas higher
levels are suggestive of progression to post-transplant
lymphoproliferative disorder.13 EBV viral load is often
elevated days to months before onset of symptoms, and
levels quickly fall once effective therapy is initiated. Sec-
ondly, nasopharyngeal carcinoma patients often have
elevated plasma levels of EBV, with advanced stage
patients having higher levels than patients with localized
disease.14 After therapy, EBV is undetectable in patients
who remain in remission, while it is measurable in those
destined to relapse.14
The cell-free EBV DNA found in plasma or serum of
patients with EBV-related neoplasia is thought to be un-
encapsidated, suggesting that it arose from apoptosis or
necrosis of infected cells.15,16 On the other hand, many
infectious mononucleosis patients have a mixture of virion
and un-encapsidated EBV DNA in their plasma, suggest-
ing that viral replication contributes to the process by
which EBV DNA accumulates in their plasma.16 Further
studies of infectious mononucleosis patients are war-
ranted to determine the relative efficacy of EBV viral load
and serological tests in confirming a clinical diagnosis; a
recent study showed that EBV viral load was false nega-
tive in five of 30 heterophile antibody-positive cases
(17%).16
In conclusion, the quantitative nature of the assays
described herein helps distinguish EBV-related disease
from incidental infection. While the BamH1W and EBNA1
assays seem most suitable for clinical applications, the
full battery of assays can be used to screen for viral
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genomic alterations. Their applicability to DNA extracted
from paraffin sections allows them to be used retrospec-
tively and in cases for which fresh tissue is not available.
Their use in plasma may obviate the need for biopsy in
selected clinical situations. Further work must be done on
larger series of cases to confirm the results of this pilot
study and to define the criteria for altering management
based on viral load results. Furthermore, the incidence of
and possible pathogenicity of genetic defects in the tar-
geted gene segments must be explored.
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